SpyGlass Pharma, Inc. Common Stock (SGP)
SpyGlass Pharma, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $34.45, up 0.00% on the session, giving a market capitalisation of $1.15B. On trailing twelve-month figures it carries a trailing P/E of -20.75, a net margin of 0.0%. Its beta of -0.89 implies it has historically moved less than the broad market.
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
SpyGlass Pharma, Inc. Common Stock is most often compared with the following Healthcare names: